L
Larisa H. Cavallari
Researcher at University of Florida
Publications - 221
Citations - 6723
Larisa H. Cavallari is an academic researcher from University of Florida. The author has contributed to research in topics: Warfarin & VKORC1. The author has an hindex of 40, co-authored 196 publications receiving 5206 citations. Previous affiliations of Larisa H. Cavallari include University of Messina & The American College of Financial Services.
Papers
More filters
Journal ArticleDOI
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.
Julie A. Johnson,Kelly E. Caudle,Li Gong,Michelle Whirl-Carrillo,Charles M. Stein,Stuart A. Scott,Lee Mt,Brian F. Gage,Stephen E. Kimmel,Minoli A. Perera,Jeffrey L. Anderson,Munir Pirmohamed,Teri E. Klein,Nita A. Limdi,Larisa H. Cavallari,Mia Wadelius +15 more
TL;DR: This document is an update to the 2011 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing and incorporates recommendations for adult and pediatric patients that are specific to continental ancestry.
Journal ArticleDOI
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups
Nita A. Limdi,Mia Wadelius,Larisa H. Cavallari,Niclas Eriksson,Dana C. Crawford,Ming Ta Michael Lee,Chien-Hsiun Chen,Alison A. Motsinger-Reif,Hersh Sagreiya,Nianjun Liu,Alan H.B. Wu,Brian F. Gage,Andrea L. Jorgensen,Munir Pirmohamed,Jae-Gook Shin,Guilherme Suarez-Kurtz,Stephen E. Kimmel,Julie A. Johnson,Teri E. Klein,Michael J. Wagner +19 more
TL;DR: Clinicians should recognize that, although at a population level, the contribution of VKORC1 toward dose requirements is higher in whites than in nonwhites; genotype predicts similar dose requirements across racial groups.
Journal ArticleDOI
Genetic variants associated with warfarin dose in African- American individuals: a genome-wide association study
Minoli A. Perera,Larisa H. Cavallari,Nita A. Limdi,Eric R. Gamazon,Anuar Konkashbaev,Roxana Daneshjou,Anna Pluzhnikov,Dana C. Crawford,Jelai Wang,Nianjun Liu,Nicholas P. Tatonetti,Stephane Bourgeois,Harumi Takahashi,Yukiko Bradford,Benjamin Burkley,Robert J. Desnick,Jonathan L. Halperin,Sherief Khalifa,Taimour Y. Langaee,Steven A. Lubitz,Edith A. Nutescu,Matthew T. Oetjens,Mohamed H. Shahin,Shitalben R. Patel,Hersh Sagreiya,Matthew Tector,Karen E. Weck,Mark J. Rieder,Stuart A. Scott,Alan H.B. Wu,James K. Burmester,Mia Wadelius,Panos Deloukas,Michael J. Wagner,Taisei Mushiroda,Michiaki Kubo,Dan M. Roden,Nancy J. Cox,Russ B. Altman,Teri E. Klein,Yusuke Nakamura,Julie A. Johnson +41 more
TL;DR: A novel CYP2C single nucleotide polymorphism exerts a clinically relevant effect on warfarin dose in African Americans, independent of CYP 2C9*2 and CYP9*3, and incorporation of this variant into pharmacogenetic dosing algorithms could improve warFarin dose prediction in this population.
Journal ArticleDOI
Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement.
Danxin Wang,Hui-Zi Chen,Kathryn M. Momary,Larisa H. Cavallari,Julie A. Johnson,Wolfgang Sadee +5 more
TL;DR: A clinical association study demonstrated that promoter SNP -1639G>A, and the tightly linked intron1 SNP 1173C>T, predict warfarin dose more accurately than intron 2 SNP 1542G>C in blacks.
Journal ArticleDOI
The IGNITE network: a model for genomic medicine implementation and research
Kristin Weitzel,Madeline Alexander,Barbara A. Bernhardt,Neil Calman,David J. Carey,Larisa H. Cavallari,Julie R. Field,Diane Hauser,Heather Junkins,Phillip A. Levin,Kenneth D. Levy,Ebony B. Madden,Teri A. Manolio,Jacqueline A. Odgis,Lori A. Orlando,Reed E. Pyeritz,R. Ryanne Wu,Alan R. Shuldiner,Alan R. Shuldiner,Erwin P. Bottinger,Joshua C. Denny,Paul R. Dexter,David A. Flockhart,Carol R. Horowitz,Julie A. Johnson,Stephen E. Kimmel,Mia A. Levy,Toni I. Pollin,Geoffrey S. Ginsburg +28 more
TL;DR: The IGNITE Network is an innovative series of projects and pilot demonstrations aiming to enhance translation of validated actionable genomic information into clinical settings and develop and use measures of outcome in response to genome-based clinical interventions using a pragmatic framework.